Amicus Therapeutics is a biopharmaceutical company in the United States of America. It started operating in the February of 2002 with headquarters set up in Cranbury, new jersey. The company has as chief executive officer Mr. John F. Crowley who has been with Amicus Therapeutics for many years.
The company of Amicus Therapeutics is focused on creating therapies for disorders with the collective name of lysosomal storage disorders. Amicus Therapeutics is also sharply focused on conducting research. In fact, the company has a couple of sites for research – one in New Jersey and another in San Diego.
The journey of the business of Amicus Therapeutics has been eventful. Up until 2009, Amicus Therapeutics was doing quite well. The company expanded and started up its second research location in 2008 in San Diego.
However, in 2009, Amicus Therapeutics was faced with a major setback. It had not manufacture power of its own, and it had been relying on a contract with Shire. Over the next couple of years, Amicus Therapeutics received grants from foundations such as The Michael J. Fox Foundation, the Alzheimer’s Drug Discovery Foundation, and a few others.
By 2013, Amicus Therapeutics was restored to its former self, and it even took on a few projects to expand the business. Towards the end of 2013, in November, Amicus Therapeutics made its first acquisition. Callidus Biopharma was obtained as well as some proprietary materials as well as intellectual property for a therapy treatment, again, based on enzyme replacement. After a couple of years, Amicus Therapeutics had another acquisition, and it obtained Scioderm for the cost of almost one billion dollars.
Amicus Therapeutics has as a leader the CEO Mr. John F. Crowley who has been a part of the company since the years of 2005. Five years later, in 2010, CEO Mr. John F. Crowley also assumed the responsibilities of chairman of the board. The previous chairman took up the position of Lead Independent Director instead.
Over the past couple of years, Amicus Therapeutics has been growing steadily in the industry of biopharmaceuticals. The company currently has well over a hundred employees and is undergoing an expansion project.